help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ott, S. M.
Right arrow Articles by Watts, N. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ott, S. M.
Right arrow Articles by Watts, N. B.

Journal of Clinical Endocrinology & Metabolism, Vol 78, 968-972, Copyright © 1994 by Endocrine Society

ARTICLES

Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis

SM Ott, GC Woodson, WE Huffer, PD Miller and NB Watts
Division of Metabolism, University of Washington, Seattle 98195.

The purpose of this study was to examine bone histomorphometry before and after 2 yr of a double blind trial of etidronate to determine whether etidronate was associated with the development of osteomalacia and to clarify the mechanism of action. Sixty-eight postmenopausal women with vertebral compression fractures from 3 clinical centers received 1 g phosphate or placebo twice daily on days 1-3, 400 mg etidronate or placebo daily on days 4-17, and 0.5 g calcium daily on days 18-91. This cycle was given eight times. Iliac crest bone was biopsied after tetracycline labeling. None of the patients developed osteomalacia. The placebo/placebo group lost significantly more bone volume than the other groups. The change in mineralizing surface was significantly different among groups due to the decrease in the placebo/etidronate group. Within groups, placebo/placebo showed a decrease in bone volume without other changes. Phosphate/placebo showed no changes. Placebo/etidronate showed decreases in osteoid volume, osteoid surface, mineralizing surface, bone formation rate, and activation frequency. The only change in phosphate/etidronate was a decrease in osteoid surface. We conclude that 2-yr treatment with cyclical etidronate does not cause osteomalacia and that the mechanism for the increased bone mass is probably a decreased activation frequency.


This article has been cited by other articles:


Home page
 JBJSHome page
C. D. Morris and T. A. Einhorn
Bisphosphonates in Orthopaedic Surgery
J. Bone Joint Surg. Am., July 1, 2005; 87(7): 1609 - 1618.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
J. Compston
Bone Histomorphometry -- The Renaissance?
IBMS BoneKEy, May 1, 2004; 1(5): 9 - 12.
[Full Text] [PDF]

Home page
 ThoraxHome page
S. COWAN, S. MORIN, and P. ERNST
Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases
Thorax, May 1, 1998; 53(5): 331 - 332.
[Full Text]

Home page
 NEJMHome page
R. Eastell
Treatment of Postmenopausal Osteoporosis
N. Engl. J. Med., March 12, 1998; 338(11): 736 - 746.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society